This article has an addendum: Informed patient consent was obtained.
Original article: Oncotarget. 2019; 10:6038–6042. 6038-6042. https://doi.org/10.18632/oncotarget.27203
. 2023 May 10;14:438. doi: 10.18632/oncotarget.28428
Addendum: Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
Mayank Rao
1, Meenakshi Bhattacharjee
2, Scott Shepard
3, Sigmund Hsu
1,✉
Mayank Rao
1The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Find articles by Mayank Rao
Meenakshi Bhattacharjee
2Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Find articles by Meenakshi Bhattacharjee
Scott Shepard
3Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA
Find articles by Scott Shepard
Sigmund Hsu
1The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
Find articles by Sigmund Hsu
1The Vivian L. Smith Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
2Department of Pathology and Laboratory Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
3Department of Neurosurgery, Temple University School of Medicine, Philadelphia, PA 19140, USA
✉
Correspondence to: Sigmund Hsu, email : Sigmund.Hsu@uth.tmc.edu
Collection date 2023.
Copyright: © 2023 Rao et al.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PMCID: PMC10171364 PMID: 37163235